ceftazidime avibactam
Selected indexed studies
- Ceftazidime-avibactam. (Rev Esp Quimioter, 2022) [PMID:35488824]
- Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. (Antimicrob Agents Chemother, 2022) [PMID:35980232]
- Ceftazidime-avibactam. (Rev Esp Quimioter, 2021) [PMID:34598423]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ceftazidime-avibactam. (2022) pubmed
- Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. (2022) pubmed
- Ceftazidime-avibactam. (2021) pubmed
- Resistance to ceftazidime-avibactam and underlying mechanisms. (2020) pubmed
- Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. (2020) pubmed
- Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections? (2021) pubmed
- Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. (2017) pubmed
- Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales. (2021) pubmed
- Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis. (2024) pubmed
- Ceftazidime/Avibactam Monotherapy Versus Other Antibiotics: Where Do We Stand? (2025) pubmed